trimethyloxamine has been researched along with Chronic Kidney Diseases in 65 studies
trimethyloxamine: used in manufacture of quaternary ammonium cpds; insect attractant; warming agent for gas; oxidant; structure
trimethylamine N-oxide : A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Offspring hypertension is associated with increases in the plasma TMAO concentration and oxidative stress and shifts in gut microbiota." | 5.91 | Iodomethylcholine Inhibits Trimethylamine-N-Oxide Production and Averts Maternal Chronic Kidney Disease-Programmed Offspring Hypertension. ( Chang-Chien, GP; Hou, CY; Hsu, CN; Lin, S; Tain, YL, 2023) |
| " More specifically, we review data on the following: (i) tryptophan metabolites and chronic kidney disease onset, illustrating the interpretation of metabolite data in the context of established biochemical pathways; (ii) trimethylamine-N-oxide and cardiovascular disease in chronic kidney disease, illustrating the integration of exogenous and endogenous inputs to the blood metabolome; and (iii) renal mitochondrial function in diabetic kidney disease and acute kidney injury, illustrating the potential for rapid translation of metabolite data for diagnostic or therapeutic aims." | 4.95 | An overview of renal metabolomics. ( Kalim, S; Rhee, EP, 2017) |
| " Trimethylamine-N-oxide (TMAO) and trimethylamine (TMA) are gut microbiota-derived metabolites, and both are known uraemic toxins that are implicated in CKD, atherosclerosis, colorectal cancer and cardiovascular risk." | 4.02 | Rapid Detection of Gut Microbial Metabolite Trimethylamine N-Oxide for Chronic Kidney Disease Prevention. ( Chang, YC; Chu, YH; Tain, YL; Wang, CC; Wang, CH; Yang, HW, 2021) |
| "2% adenine diet for 14 weeks developed CKD with elevated plasma levels of TMAO, provision of a non-lethal inhibitor of gut microbial trimethylamine (TMA) production, iodomethylcholine (IMC), significantly reduced multiple markers of renal injury (plasma creatinine, cystatin C, FGF23, and TMAO), reduced histopathologic evidence of fibrosis, and markedly attenuated development of microalbuminuria." | 4.02 | Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice. ( Charugundla, S; Guo, F; Hazen, SL; Jia, X; Kaczor-Urbanowicz, KE; Lusis, AJ; Magyar, C; Miikeda, A; Nicholas, SB; Pellegrini, M; Shih, DM; Wang, Z; Zhang, W; Zhou, Z; Zuckerman, J, 2021) |
| "Gut microbial metabolism of dietary choline, a nutrient abundant in a Western diet, produces trimethylamine (TMA) and the atherothrombosis- and fibrosis-promoting metabolite TMA-N-oxide (TMAO)." | 3.96 | Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease. ( Buffa, JA; DiDonato, JA; Gupta, N; Hazen, SL; Ho, KJ; Li, L; Roberts, AB; Sangwan, N; Skye, SM; Tang, WHW; Varga, J, 2020) |
| " We aimed to assess the correlation between circulating TMAO concentration and the risk of all-cause and cardiovascular death in CKD patients of different dialysis statuses and different races by dose-response analyses, and the underlying mechanisms were also explored by analyzing the correlations of TMAO with glomerular filtration rate (GFR) and inflammation." | 3.01 | Gut microbiota-derived trimethylamine N-oxide is associated with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and dose-response meta-analysis. ( Guo, J; Li, Y; Liu, W; Liu, Y; Lu, H; Zhang, M; Zheng, H, 2023) |
| "Choline is a water-soluble nutrient essential for human life." | 2.66 | The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases. ( Allison, J; Arboleya, S; Arias, JL; Arias, N; Gueimonde, M; Higarza, SG; Kaliszewska, A, 2020) |
| "Offspring hypertension is associated with increases in the plasma TMAO concentration and oxidative stress and shifts in gut microbiota." | 1.91 | Iodomethylcholine Inhibits Trimethylamine-N-Oxide Production and Averts Maternal Chronic Kidney Disease-Programmed Offspring Hypertension. ( Chang-Chien, GP; Hou, CY; Hsu, CN; Lin, S; Tain, YL, 2023) |
| "This case-cohort study included Chronic Renal Insufficiency Cohort participants with baseline diabetes, estimated glomerular filtration rate <60 mL/min/1." | 1.91 | Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. ( Anderson, AH; Bhat, Z; Brown, J; Brunengraber, H; Charleston, J; Chen, J; Feldman, HI; He, J; Hostetter, TH; Hsu, CY; Ix, JH; Kimmel, PL; Mehta, R; Rao, P; Sapa, H; Schelling, JR; Schrauben, SJ; Seegmiller, JC; Shafi, T; Shlipak, MG; Townsend, R; Vasan, RS; Xie, D; Zhang, X, 2023) |
| "Notably, endotoxemia was used as a surrogate marker of gut leakage in patients." | 1.91 | TMAO reductase, a biomarker for gut permeability defect induced inflammation, in mouse model of chronic kidney disease and dextran sulfate solution-induced mucositis. ( Boonhai, S; Bootdee, K; Leelahavanichkul, A; Saisorn, W; Sitticharoenchai, P; Takkavatakarn, K; Tiranathanagul, K; Tungsanga, S, 2023) |
| "Vascular calcification is highly prevalent in patients with chronic kidney disease." | 1.56 | Trimethylamine-N-Oxide Promotes Vascular Calcification Through Activation of NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome and NF-κB (Nuclear Factor κB) Signals. ( Chen, M; Chen, Y; Li, Y; Li, Z; Liu, H; Liu, X; Lu, L; Ou, C; Yan, J; Yang, P; Zhang, X; Zhong, X, 2020) |
| "Trimethylamine was used as a probe substrate to assess FMO activity." | 1.51 | Metabolic Activation of Flavin Monooxygenase-mediated Trimethylamine-N-Oxide Formation in Experimental Kidney Disease. ( Leblond, FA; Nolin, TD; Pichette, V; Prokopienko, AJ; Schrum, DP; Stubbs, JR; West, RE, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 27 (41.54) | 24.3611 |
| 2020's | 38 (58.46) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, YC | 1 |
| Chu, YH | 1 |
| Wang, CC | 1 |
| Wang, CH | 2 |
| Tain, YL | 2 |
| Yang, HW | 1 |
| Zhang, L | 2 |
| Xie, F | 1 |
| Tang, H | 2 |
| Zhang, X | 5 |
| Hu, J | 1 |
| Zhong, X | 2 |
| Gong, N | 1 |
| Lai, Y | 2 |
| Zhou, M | 2 |
| Tian, J | 1 |
| Zhou, Z | 3 |
| Xie, L | 1 |
| Hu, Z | 2 |
| Zhu, F | 2 |
| Jiang, J | 1 |
| Nie, J | 3 |
| Chen, G | 1 |
| He, L | 1 |
| Dou, X | 1 |
| Liu, T | 1 |
| Hu, DY | 1 |
| Wu, MY | 1 |
| Chen, GQ | 1 |
| Deng, BQ | 1 |
| Yu, HB | 1 |
| Huang, J | 1 |
| Luo, Y | 1 |
| Li, MY | 1 |
| Zhao, DK | 1 |
| Liu, JY | 1 |
| Zhou, X | 1 |
| Zhang, B | 1 |
| Zhao, X | 1 |
| Lin, Y | 1 |
| Zhuang, Y | 1 |
| Guo, J | 2 |
| Wang, S | 2 |
| Hsu, BG | 1 |
| Lin, YL | 1 |
| Lai, YH | 1 |
| Tsai, JP | 1 |
| Kapetanaki, S | 1 |
| Kumawat, AK | 1 |
| Persson, K | 1 |
| Demirel, I | 1 |
| Dai, L | 1 |
| Massy, ZA | 1 |
| Stenvinkel, P | 8 |
| Chesnaye, NC | 1 |
| Larabi, IA | 1 |
| Alvarez, JC | 2 |
| Caskey, FJ | 1 |
| Torino, C | 1 |
| Porto, G | 1 |
| Szymczak, M | 1 |
| Krajewska, M | 1 |
| Drechsler, C | 1 |
| Wanner, C | 1 |
| Jager, KJ | 1 |
| Dekker, FW | 1 |
| Evenepoel, P | 2 |
| Evans, M | 1 |
| Saaoud, F | 4 |
| Liu, L | 3 |
| Xu, K | 3 |
| Cueto, R | 3 |
| Shao, Y | 3 |
| Lu, Y | 3 |
| Sun, Y | 4 |
| Snyder, NW | 3 |
| Wu, S | 3 |
| Yang, L | 3 |
| Zhou, Y | 3 |
| Williams, DL | 3 |
| Li, C | 3 |
| Martinez, L | 3 |
| Vazquez-Padron, RI | 3 |
| Zhao, H | 3 |
| Jiang, X | 3 |
| Wang, H | 4 |
| Yang, X | 4 |
| Yong, C | 4 |
| Huang, G | 3 |
| Ge, H | 3 |
| Zhu, Y | 3 |
| Yang, Y | 3 |
| Yu, Y | 3 |
| Tian, F | 3 |
| Gao, K | 4 |
| Zhou, E | 3 |
| Chang-Chien, GP | 1 |
| Lin, S | 1 |
| Hou, CY | 1 |
| Hsu, CN | 1 |
| Huang, GS | 1 |
| Ge, HW | 1 |
| Sun, QM | 1 |
| Zhou, EC | 1 |
| Pan, S | 1 |
| Zhao, D | 1 |
| Duan, S | 1 |
| Chen, X | 1 |
| Mafra, D | 5 |
| Kemp, JA | 1 |
| Leal, VO | 1 |
| Cardozo, L | 1 |
| Borges, NA | 3 |
| Alvarenga, L | 1 |
| Teixeira, KTR | 1 |
| Fonseca, RID | 1 |
| Menezes, LRA | 1 |
| Santana-Filho, AP | 1 |
| Schiefer, EM | 1 |
| Pecoits-Filho, R | 1 |
| Stinghen, AEM | 1 |
| Sassaki, GL | 1 |
| Schrauben, SJ | 1 |
| Sapa, H | 2 |
| Xie, D | 1 |
| Anderson, AH | 1 |
| Shlipak, MG | 1 |
| Hsu, CY | 1 |
| Shafi, T | 1 |
| Mehta, R | 1 |
| Bhat, Z | 1 |
| Brown, J | 1 |
| Charleston, J | 1 |
| Chen, J | 1 |
| He, J | 1 |
| Ix, JH | 1 |
| Rao, P | 1 |
| Townsend, R | 1 |
| Kimmel, PL | 1 |
| Vasan, RS | 1 |
| Feldman, HI | 1 |
| Seegmiller, JC | 1 |
| Brunengraber, H | 1 |
| Hostetter, TH | 1 |
| Schelling, JR | 1 |
| Li, Y | 2 |
| Lu, H | 1 |
| Zhang, M | 1 |
| Zheng, H | 1 |
| Liu, Y | 3 |
| Liu, W | 1 |
| Korytowska-Przybylska, N | 1 |
| Michorowska, S | 1 |
| Wyczałkowska-Tomasik, A | 1 |
| Pączek, L | 1 |
| Giebułtowicz, J | 1 |
| Hobson, S | 1 |
| Qureshi, AR | 4 |
| Ripswedan, J | 1 |
| Wennberg, L | 1 |
| de Loor, H | 1 |
| Ebert, T | 2 |
| Söderberg, M | 1 |
| Kublickiene, K | 2 |
| Craven, H | 1 |
| Erlandsson, H | 1 |
| McGuinness, D | 1 |
| McGuinness, DH | 1 |
| Ijaz, UZ | 1 |
| Bergman, P | 5 |
| Shiels, PG | 2 |
| Rigothier, C | 1 |
| Catros, S | 1 |
| Bénard, A | 1 |
| Samot, J | 1 |
| Quintin, O | 1 |
| Combe, C | 1 |
| Larabi, I | 1 |
| Massy, Z | 1 |
| Chan, MM | 1 |
| Fong, D | 1 |
| Hill, E | 1 |
| Negrea, L | 1 |
| Bame, K | 1 |
| Hostetter, T | 1 |
| Barkoukis, H | 1 |
| Dusso, A | 1 |
| Dobre, M | 1 |
| Pelletier, CC | 1 |
| Croyal, M | 1 |
| Ene, L | 1 |
| Aguesse, A | 1 |
| Billon-Crossouard, S | 1 |
| Krempf, M | 1 |
| Lemoine, S | 1 |
| Guebre-Egziabher, F | 1 |
| Juillard, L | 1 |
| Soulage, CO | 1 |
| Prokopienko, AJ | 1 |
| West, RE | 1 |
| Schrum, DP | 1 |
| Stubbs, JR | 2 |
| Leblond, FA | 1 |
| Pichette, V | 1 |
| Nolin, TD | 2 |
| Taguchi, K | 2 |
| Elias, BC | 2 |
| Brooks, CR | 2 |
| Ueda, S | 1 |
| Fukami, K | 2 |
| Dai, Q | 2 |
| Zhang, H | 2 |
| Yang, P | 1 |
| Liu, X | 1 |
| Lu, L | 1 |
| Chen, Y | 2 |
| Li, Z | 1 |
| Liu, H | 1 |
| Ou, C | 1 |
| Yan, J | 1 |
| Chen, M | 1 |
| Gupta, N | 1 |
| Buffa, JA | 2 |
| Roberts, AB | 1 |
| Sangwan, N | 1 |
| Skye, SM | 1 |
| Li, L | 1 |
| Ho, KJ | 1 |
| Varga, J | 1 |
| DiDonato, JA | 1 |
| Tang, WHW | 2 |
| Hazen, SL | 3 |
| Özcan-Ekşi, EE | 1 |
| Ekşi, MŞ | 1 |
| Turgut, VU | 1 |
| Canbolat, Ç | 1 |
| Pamir, MN | 1 |
| Nocentini, A | 1 |
| Del Prete, S | 1 |
| Mastrolorenzo, MD | 1 |
| Donald, WA | 1 |
| Capasso, C | 1 |
| Supuran, CT | 1 |
| Zheng, Y | 1 |
| Tang, Z | 1 |
| You, L | 1 |
| Wu, Y | 2 |
| Liu, J | 1 |
| Xue, J | 1 |
| Wiese, GN | 1 |
| Biruete, A | 1 |
| Moorthi, RN | 1 |
| Moe, SM | 1 |
| Lindemann, SR | 1 |
| Hill Gallant, KM | 1 |
| Arias, N | 1 |
| Arboleya, S | 1 |
| Allison, J | 1 |
| Kaliszewska, A | 1 |
| Higarza, SG | 1 |
| Gueimonde, M | 1 |
| Arias, JL | 1 |
| Ravid, JD | 1 |
| Chitalia, VC | 1 |
| Guo, F | 2 |
| Zeng, X | 1 |
| Tan, Z | 1 |
| Ouyang, D | 1 |
| Painer, J | 1 |
| Giroud, S | 1 |
| Stalder, G | 1 |
| Göritz, F | 1 |
| Vetter, S | 1 |
| Bieber, C | 1 |
| Fröbert, O | 1 |
| Arnemo, JM | 1 |
| Zedrosser, A | 1 |
| Redtenbacher, I | 1 |
| Johnson, RJ | 1 |
| Zhao, J | 1 |
| Ning, X | 1 |
| Liu, B | 1 |
| Dong, R | 1 |
| Bai, M | 1 |
| Sun, S | 1 |
| Zhang, W | 1 |
| Miikeda, A | 1 |
| Zuckerman, J | 1 |
| Jia, X | 1 |
| Charugundla, S | 1 |
| Kaczor-Urbanowicz, KE | 1 |
| Magyar, C | 1 |
| Wang, Z | 2 |
| Pellegrini, M | 1 |
| Nicholas, SB | 1 |
| Lusis, AJ | 1 |
| Shih, DM | 1 |
| Flores-Guerrero, JL | 1 |
| Osté, MCJ | 1 |
| Baraldi, PB | 1 |
| Connelly, MA | 1 |
| Garcia, E | 1 |
| Navis, G | 1 |
| Bakker, SJL | 1 |
| Dullaart, RPF | 1 |
| Wang, L | 1 |
| Zhu, N | 1 |
| Jia, J | 1 |
| Gu, L | 1 |
| Du, Y | 1 |
| Tang, G | 1 |
| Wang, X | 1 |
| Yang, M | 1 |
| Yuan, W | 1 |
| Zhou, J | 1 |
| Wang, D | 1 |
| Li, B | 1 |
| Li, X | 1 |
| Lai, X | 1 |
| Lei, S | 1 |
| Li, N | 1 |
| Boonhai, S | 1 |
| Bootdee, K | 1 |
| Saisorn, W | 1 |
| Takkavatakarn, K | 1 |
| Sitticharoenchai, P | 1 |
| Tungsanga, S | 1 |
| Tiranathanagul, K | 1 |
| Leelahavanichkul, A | 1 |
| Xu, KY | 1 |
| Xia, GH | 1 |
| Lu, JQ | 1 |
| Chen, MX | 1 |
| Zhen, X | 1 |
| You, C | 1 |
| Zhou, HW | 1 |
| Yin, J | 1 |
| Fernandez-Prado, R | 1 |
| Esteras, R | 1 |
| Perez-Gomez, MV | 1 |
| Gracia-Iguacel, C | 1 |
| Gonzalez-Parra, E | 1 |
| Sanz, AB | 1 |
| Ortiz, A | 1 |
| Sanchez-Niño, MD | 1 |
| Tomlinson, JAP | 1 |
| Wheeler, DC | 1 |
| Li, T | 1 |
| Gua, C | 1 |
| Wu, B | 1 |
| Cardozo, LFMF | 1 |
| Anjos, JS | 1 |
| Black, AP | 1 |
| Moraes, C | 3 |
| Lindholm, B | 3 |
| Kalim, S | 2 |
| Wald, R | 1 |
| Yan, AT | 1 |
| Goldstein, MB | 1 |
| Kiaii, M | 1 |
| Xu, D | 1 |
| Berg, AH | 1 |
| Clish, C | 1 |
| Thadhani, R | 1 |
| Rhee, EP | 2 |
| Perl, J | 1 |
| Li, DY | 1 |
| Stockler-Pinto, MB | 1 |
| El-Deeb, OS | 1 |
| Atef, MM | 1 |
| Hafez, YM | 1 |
| Tang, WH | 1 |
| Kennedy, DJ | 1 |
| Agatisa-Boyle, B | 1 |
| Li, XS | 1 |
| Levison, BS | 1 |
| Fogelman, AM | 1 |
| Quante, M | 1 |
| House, JA | 1 |
| Ocque, AJ | 1 |
| Zhang, S | 1 |
| Johnson, C | 1 |
| Kimber, C | 1 |
| Schmidt, K | 1 |
| Gupta, A | 1 |
| Wetmore, JB | 1 |
| Spertus, JA | 1 |
| Yu, AS | 1 |
| Fouque, D | 1 |
| Amaral, AC | 1 |
| Aron-Wisnewsky, J | 1 |
| Clément, K | 1 |
| Mafune, A | 1 |
| Iwamoto, T | 1 |
| Tsutsumi, Y | 1 |
| Nakashima, A | 1 |
| Yamamoto, I | 1 |
| Yokoyama, K | 1 |
| Yokoo, T | 1 |
| Urashima, M | 1 |
| Missailidis, C | 1 |
| Hällqvist, J | 1 |
| Barany, P | 1 |
| Heimbürger, O | 1 |
| Kim, RB | 1 |
| Morse, BL | 1 |
| Djurdjev, O | 1 |
| Tang, M | 1 |
| Muirhead, N | 1 |
| Barrett, B | 1 |
| Holmes, DT | 1 |
| Madore, F | 1 |
| Clase, CM | 1 |
| Rigatto, C | 1 |
| Levin, A | 1 |
| Robinson-Cohen, C | 1 |
| Newitt, R | 1 |
| Shen, DD | 1 |
| Rettie, AE | 1 |
| Kestenbaum, BR | 1 |
| Himmelfarb, J | 1 |
| Yeung, CK | 1 |
| Ottiger, M | 1 |
| Nickler, M | 1 |
| Steuer, C | 1 |
| Odermatt, J | 1 |
| Huber, A | 1 |
| Christ-Crain, M | 1 |
| Henzen, C | 1 |
| Hoess, C | 1 |
| Thomann, R | 1 |
| Zimmerli, W | 1 |
| Mueller, B | 1 |
| Schuetz, P | 1 |
| Velasquez, MT | 1 |
| Ramezani, A | 1 |
| Manal, A | 1 |
| Raj, DS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Washed Microbiota Transplantation (WMT) for Chronic Kidney Disease (CKD): a Open Label, Multicenter Trial[NCT05838118] | 100 participants (Anticipated) | Interventional | 2023-04-20 | Recruiting | |||
| The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4: a Protocol of a Randomized, Parallel, Controlled Trial[NCT03596749] | Phase 3 | 80 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for trimethyloxamine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Association of Trimethylamine-N-Oxide Levels with Risk of Cardiovascular Disease and Mortality among Elderly Subjects: A Systematic Review and Meta-Analysis.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Heart Failure; Humans; Methylamines; Oxides; Prospective | 2022 |
[Effect of traditional Chinese medicine in attenuating chronic kidney disease and its complications by regulating gut microbiota-derived metabolite trimethylamine N-oxide: a review].
Topics: Gastrointestinal Microbiome; Humans; Medicine, Chinese Traditional; Renal Insufficiency, Chronic | 2023 |
The role of gut-dependent molecule trimethylamine N-oxide as a novel target for the treatment of chronic kidney disease.
Topics: Gastrointestinal Microbiome; Humans; Kidney; Methylamines; Renal Insufficiency, Chronic | 2023 |
Consumption of Fish in Chronic Kidney Disease - A Matter of Depth.
Topics: Animals; Gastrointestinal Microbiome; Methylamines; Renal Insufficiency; Renal Insufficiency, Chroni | 2023 |
Gut microbiota-derived trimethylamine N-oxide is associated with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and dose-response meta-analysis.
Topics: Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Inflammation; Renal Insufficiency, Chr | 2023 |
The Microbial Metabolite Trimethylamine N-Oxide Links Vascular Dysfunctions and the Autoimmune Disease Rheumatoid Arthritis.
Topics: Amyloid; Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Cardiovascular Diseases; Diet; Dysbios | 2019 |
Uremic Toxin-Targeting as a Therapeutic Strategy for Preventing Cardiorenal Syndrome.
Topics: Arginine; Cardio-Renal Syndrome; Glycation End Products, Advanced; Humans; Methylamines; Renal Insuf | 2019 |
Plant-Based Diets, the Gut Microbiota, and Trimethylamine N-Oxide Production in Chronic Kidney Disease: Therapeutic Potential and Methodological Considerations.
Topics: Animals; Diet; Diet, Vegetarian; Gastrointestinal Microbiome; Humans; Methylamines; Renal Insufficie | 2021 |
The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases.
Topics: Animals; Biological Availability; Cardiovascular Diseases; Choline; Diet; Dysbiosis; Gastrointestina | 2020 |
Molecular Mechanisms Underlying the Cardiovascular Toxicity of Specific Uremic Solutes.
Topics: Basic Helix-Loop-Helix Transcription Factors; Blood Platelets; Cardiovascular Diseases; Disease Prog | 2020 |
Specific alterations in gut microbiota in patients with chronic kidney disease: an updated systematic review.
Topics: Bacteria; Dysbiosis; Gastrointestinal Microbiome; Humans; Methylamines; Renal Insufficiency, Chronic | 2021 |
Dysbiosis-Related Advanced Glycation Endproducts and Trimethylamine N-Oxide in Chronic Kidney Disease.
Topics: Animals; Cardiovascular Diseases; Disease Progression; Dysbiosis; Gastrointestinal Microbiome; Glyca | 2021 |
Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease.
Topics: Cardiovascular Diseases; Carnitine; Choline; Diet; Gastrointestinal Microbiome; Humans; Methylamines | 2017 |
The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease.
Topics: Biomarkers; Cardiovascular Diseases; Diet Therapy; Gastrointestinal Microbiome; Humans; Kidney; Lipi | 2017 |
Red meat intake in chronic kidney disease patients: Two sides of the coin.
Topics: Cardiovascular Diseases; Diet, Protein-Restricted; Dietary Fats; Dietary Proteins; Gastrointestinal | 2018 |
Contributory Role of Gut Microbiota and Their Metabolites Toward Cardiovascular Complications in Chronic Kidney Disease.
Topics: Animals; Cardiovascular Diseases; Cresols; Diet Therapy; Dietary Supplements; Dysbiosis; Enzyme Inhi | 2018 |
Trimethylamine N-Oxide From Gut Microbiota in Chronic Kidney Disease Patients: Focus on Diet.
Topics: Animals; Cardiovascular Diseases; Carnitine; Choline; Diet, Protein-Restricted; Disease Models, Anim | 2015 |
The gut microbiome, diet, and links to cardiometabolic and chronic disorders.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Chronic Disease; Diet; Gastrointestinal Microbiome; Hu | 2016 |
An overview of renal metabolomics.
Topics: Acute Kidney Injury; Analytic Sample Preparation Methods; Cardiovascular Diseases; Diabetic Nephropa | 2017 |
Trimethylamine N-Oxide: The Good, the Bad and the Unknown.
Topics: Animals; Cardiovascular Diseases; Gastrointestinal Microbiome; Humans; Methylamines; Renal Insuffici | 2016 |
1 trial available for trimethyloxamine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Effects of Probiotic Supplementation on Trimethylamine-N-Oxide Plasma Levels in Hemodialysis Patients: a Pilot Study.
Topics: Adult; Aged; Bifidobacterium longum; Dietary Supplements; Double-Blind Method; Female; Humans; Lacto | 2019 |
44 other studies available for trimethyloxamine and Chronic Kidney Diseases
| Article | Year |
|---|---|
Rapid Detection of Gut Microbial Metabolite Trimethylamine N-Oxide for Chronic Kidney Disease Prevention.
Topics: Atherosclerosis; Gastrointestinal Microbiome; Humans; Manganese Compounds; Methylamines; Oxides; Ren | 2021 |
Gut microbial metabolite TMAO increases peritoneal inflammation and peritonitis risk in peritoneal dialysis patients.
Topics: Adult; Animals; Cell Death; Cytokines; Epithelium; Female; Gastrointestinal Microbiome; Glucose; Hum | 2022 |
Trimethylamine-N-Oxide Aggravates Kidney Injury via Activation of p38/MAPK Signaling and Upregulation of HuR.
Topics: Animals; ELAV-Like Protein 1; Inflammation; Male; Methylamines; p38 Mitogen-Activated Protein Kinase | 2022 |
Metabolomics analysis of human plasma reveals decreased production of trimethylamine N-oxide retards the progression of chronic kidney disease.
Topics: Actins; Animals; Biomarkers; Chromatography, Liquid; Humans; Methylamines; Mice; Renal Insufficiency | 2022 |
Chlorogenic Acid Prevents Hyperuricemia Nephropathy via Regulating TMAO-Related Gut Microbes and Inhibiting the PI3K/AKT/mTOR Pathway.
Topics: Animals; Chlorogenic Acid; Fibrosis; Gastrointestinal Microbiome; Hyperuricemia; Mammals; Methylamin | 2022 |
Serum Trimethylamine N-Oxide Level Is Associated with Peripheral Arterial Stiffness in Advanced Non-Dialysis Chronic Kidney Disease Patients.
Topics: Ankle Brachial Index; C-Reactive Protein; Cardiovascular Diseases; Humans; Methylamines; Pulse Wave | 2022 |
TMAO Suppresses Megalin Expression and Albumin Uptake in Human Proximal Tubular Cells Via PI3K and ERK Signaling.
Topics: Albumins; Endocytosis; Epithelial Cells; Humans; Kidney Tubules, Proximal; Low Density Lipoprotein R | 2022 |
The association between TMAO, CMPF, and clinical outcomes in advanced chronic kidney disease: results from the European QUALity (EQUAL) Study.
Topics: Animals; Diet; Glomerular Filtration Rate; Humans; Methylamines; Red Meat; Renal Insufficiency, Chro | 2022 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Aorta- and liver-generated TMAO enhances trained immunity for increased inflammation via ER stress/mitochondrial ROS/glycolysis pathways.
Topics: Animals; Aorta; Cardiovascular Diseases; Endothelial Cells; Humans; Inflammation; Intercellular Adhe | 2023 |
Perilla frutescens L. alleviates trimethylamine N-oxide-induced apoptosis in the renal tubule by regulating ASK1-JNK phosphorylation.
Topics: Apoptosis; Humans; MAP Kinase Kinase Kinase 5; Perilla frutescens; Phosphorylation; Renal Insufficie | 2023 |
Perilla frutescens L. alleviates trimethylamine N-oxide-induced apoptosis in the renal tubule by regulating ASK1-JNK phosphorylation.
Topics: Apoptosis; Humans; MAP Kinase Kinase Kinase 5; Perilla frutescens; Phosphorylation; Renal Insufficie | 2023 |
Perilla frutescens L. alleviates trimethylamine N-oxide-induced apoptosis in the renal tubule by regulating ASK1-JNK phosphorylation.
Topics: Apoptosis; Humans; MAP Kinase Kinase Kinase 5; Perilla frutescens; Phosphorylation; Renal Insufficie | 2023 |
Perilla frutescens L. alleviates trimethylamine N-oxide-induced apoptosis in the renal tubule by regulating ASK1-JNK phosphorylation.
Topics: Apoptosis; Humans; MAP Kinase Kinase Kinase 5; Perilla frutescens; Phosphorylation; Renal Insufficie | 2023 |
Perilla frutescens L. alleviates trimethylamine N-oxide-induced apoptosis in the renal tubule by regulating ASK1-JNK phosphorylation.
Topics: Apoptosis; Humans; MAP Kinase Kinase Kinase 5; Perilla frutescens; Phosphorylation; Renal Insufficie | 2023 |
Perilla frutescens L. alleviates trimethylamine N-oxide-induced apoptosis in the renal tubule by regulating ASK1-JNK phosphorylation.
Topics: Apoptosis; Humans; MAP Kinase Kinase Kinase 5; Perilla frutescens; Phosphorylation; Renal Insufficie | 2023 |
Perilla frutescens L. alleviates trimethylamine N-oxide-induced apoptosis in the renal tubule by regulating ASK1-JNK phosphorylation.
Topics: Apoptosis; Humans; MAP Kinase Kinase Kinase 5; Perilla frutescens; Phosphorylation; Renal Insufficie | 2023 |
Perilla frutescens L. alleviates trimethylamine N-oxide-induced apoptosis in the renal tubule by regulating ASK1-JNK phosphorylation.
Topics: Apoptosis; Humans; MAP Kinase Kinase Kinase 5; Perilla frutescens; Phosphorylation; Renal Insufficie | 2023 |
Perilla frutescens L. alleviates trimethylamine N-oxide-induced apoptosis in the renal tubule by regulating ASK1-JNK phosphorylation.
Topics: Apoptosis; Humans; MAP Kinase Kinase Kinase 5; Perilla frutescens; Phosphorylation; Renal Insufficie | 2023 |
Iodomethylcholine Inhibits Trimethylamine-N-Oxide Production and Averts Maternal Chronic Kidney Disease-Programmed Offspring Hypertension.
Topics: Animals; Female; Humans; Hypertension; Hypertrophy; Methylamines; Oxides; Pregnancy; Rats; Renal Ins | 2023 |
Untargeted plasma
Topics: Creatinine; Ethylenediamines; Humans; Lactates; Magnetic Resonance Spectroscopy; Proton Magnetic Res | 2023 |
Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.
Topics: Arginine; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; D | 2023 |
Development of a novel method for the simultaneous detection of trimethylamine N-oxide and creatinine in the saliva of patients with chronic kidney disease - Its utility in saliva as an alternative to blood.
Topics: Biomarkers; Creatinine; Humans; Methylamines; Renal Insufficiency; Renal Insufficiency, Chronic; Sal | 2023 |
Phenylacetylglutamine and trimethylamine N-oxide: Two uremic players, different actions.
Topics: Calcium; Cross-Sectional Studies; Humans; Phosphates; Renal Insufficiency, Chronic; Vascular Calcifi | 2023 |
A normative microbiome is not restored following kidney transplantation.
Topics: Dysbiosis; Gastrointestinal Microbiome; Humans; Kidney Transplantation; Microbiota; Renal Insufficie | 2023 |
Association between Dental Scores and Saliva Uremic Toxins.
Topics: Chromatography, Liquid; Humans; Indican; Prospective Studies; Renal Insufficiency, Chronic; Saliva; | 2023 |
Effect of Oat β-Glucan Supplementation on Chronic Kidney Disease: A Feasibility Study.
Topics: Aged; Avena; beta-Glucans; Biomarkers; Diet; Dietary Supplements; Feasibility Studies; Female; Human | 2020 |
Elevation of Trimethylamine-N-Oxide in Chronic Kidney Disease: Contribution of Decreased Glomerular Filtration Rate.
Topics: Adult; Betaine; Choline; Creatinine; Female; Gastrointestinal Microbiome; Glomerular Filtration Rate | 2019 |
Metabolic Activation of Flavin Monooxygenase-mediated Trimethylamine-N-Oxide Formation in Experimental Kidney Disease.
Topics: Activation, Metabolic; Animals; Blood Urea Nitrogen; Creatinine; Cytochrome P-450 CYP1A2; Disease Mo | 2019 |
[Trimethylamine-N-oxide and cardiovascular events in chronic kidney disease].
Topics: Biomarkers; Cardiovascular Diseases; Humans; Methylamines; Oxides; Renal Insufficiency, Chronic | 2019 |
Trimethylamine-N-Oxide Promotes Vascular Calcification Through Activation of NLRP3 (Nucleotide-Binding Domain, Leucine-Rich-Containing Family, Pyrin Domain-Containing-3) Inflammasome and NF-κB (Nuclear Factor κB) Signals.
Topics: Adult; Aged; Animals; Anti-Bacterial Agents; Aorta, Thoracic; Cells, Cultured; Disease Models, Anima | 2020 |
Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease.
Topics: Animals; Bacteria; Bacterial Proteins; Choline; Disease Models, Animal; Enzyme Inhibitors; Fibrosis; | 2020 |
Topics: Aged; Amines; Amino Acids; Biomarkers; Carbonic Anhydrases; Cardiovascular Diseases; Catalysis; Cros | 2021 |
Renal function is associated with plasma trimethylamine-N-oxide, choline, L-carnitine and betaine: a pilot study.
Topics: Betaine; Biomarkers; Carnitine; Choline; Female; Glomerular Filtration Rate; Humans; Kidney; Male; M | 2021 |
Insights in the regulation of trimetylamine N-oxide production using a comparative biomimetic approach suggest a metabolic switch in hibernating bears.
Topics: Adult; Aged; Aged, 80 and over; Animals; Betaine; Biomimetics; Cardiovascular Diseases; Choline; Fem | 2020 |
Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice.
Topics: Adenine; Albuminuria; Animals; Cardiomegaly; Choline; Disease Models, Animal; Female; Fibroblast Gro | 2021 |
Association of Circulating Trimethylamine
Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Diet; Female; Glomerular Filtration Rate; Graf | 2021 |
Trimethylamine N-oxide mediated Y-box binding protein-1 nuclear translocation promotes cell cycle progression by directly downregulating Gadd45a expression in a cellular model of chronic kidney disease.
Topics: Active Transport, Cell Nucleus; Animals; Cell Cycle; Cell Cycle Proteins; Dose-Response Relationship | 2021 |
Relationship between Plasma Trimethylamine N-Oxide Levels and Renal Dysfunction in Patients with Hypertension.
Topics: Biomarkers; Cross-Sectional Studies; Female; Humans; Hypertension; Male; Methylamines; Middle Aged; | 2021 |
TMAO reductase, a biomarker for gut permeability defect induced inflammation, in mouse model of chronic kidney disease and dextran sulfate solution-induced mucositis.
Topics: Animals; Biomarkers; Colitis; Dextran Sulfate; Endotoxemia; Inflammation; Interleukin-6; Mice; Mucos | 2023 |
Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients.
Topics: Adult; Aged; Animals; Betaine; Carnitine; Case-Control Studies; Choline; Clostridiaceae; Dysbiosis; | 2017 |
Increased circulating trimethylamine N-oxide contributes to endothelial dysfunction in a rat model of chronic kidney disease.
Topics: Animals; Biomarkers; Cytokines; Endothelium, Vascular; Male; Methylamines; Rats; Rats, Sprague-Dawle | 2018 |
Extended Duration Nocturnal Hemodialysis and Changes in Plasma Metabolite Profiles.
Topics: Acetylcarnitine; Adult; Aged; Amino Acids, Branched-Chain; Case-Control Studies; Cresols; Female; Hu | 2018 |
The interplay between microbiota-dependent metabolite trimethylamine N-oxide, Transforming growth factor β/SMAD signaling and inflammasome activation in chronic kidney disease patients: A new mechanistic perspective.
Topics: Adult; Case-Control Studies; Disease Progression; Female; Humans; Interleukin-1beta; Male; Methylami | 2019 |
Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.
Topics: Aged; Aged, 80 and over; Animals; Biomarkers; Case-Control Studies; Female; Humans; Intestines; Male | 2015 |
TMAO is both a biomarker and a renal toxin.
Topics: Animals; Female; Humans; Male; Methylamines; Microbiota; Renal Insufficiency; Renal Insufficiency, C | 2015 |
You Are What You Eat: Metabolites of Gut Microbiota Provide Novel Insights into Diagnosis and Development of Chronic Kidney Disease.
Topics: Animals; Bacteria; Biomarkers; Diet; Humans; Intestinal Mucosa; Intestines; Metabolomics; Methylamin | 2015 |
Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden.
Topics: Aged; Coronary Artery Disease; Cross-Sectional Studies; Female; Humans; Kidney Transplantation; Male | 2016 |
Associations among serum trimethylamine-N-oxide (TMAO) levels, kidney function and infarcted coronary artery number in patients undergoing cardiovascular surgery: a cross-sectional study.
Topics: Aged; Biomarkers; Cardiac Surgical Procedures; Chi-Square Distribution; Chromatography, High Pressur | 2016 |
Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease.
Topics: Adult; Aged; Betaine; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Choline; Female; Fibr | 2016 |
Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events.
Topics: Aged; Aged, 80 and over; Biomarkers; Canada; Cardiovascular Diseases; Disease-Free Survival; Female; | 2016 |
Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients.
Topics: Biomarkers; Disease Progression; Female; Humans; Male; Methylamines; Middle Aged; Oxygenases; Polymo | 2016 |
Trimethylamine-N-oxide (TMAO) predicts fatal outcomes in community-acquired pneumonia patients without evident coronary artery disease.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cause of Death; Cerebrovascular Disorde | 2016 |